Demographics and cystic fibrosis (CF) therapies in 24 adults with CF at baseline (prior to commencement of lumacaftor/ivacaftor)

Age years32.6±8.6
Height cm169.0±10.4
BMI kg·m−220.3±2.7
FEV1 L1.30±0.41
FEV1 % pred34.7±7.4
FVC L2.65±0.81
FVC % pred57.8±10.0
FEF25–75% L0.51±0.19
FEF25–75% % pred13.3±4.2
Diagnosis of CF-related diabetes mellitus33.3
Diagnosis of CF-related liver disease33.3
Use of supplementary oxygen therapy0.0
Recombinant human DNase58.3
Hypertonic saline58.3
Inhaled antibiotics41.4
Oral antibiotics33.3
Inhaled corticosteroids87.5
Oral corticosteroids4.2
Long-acting β2-agonists91.7
Long-acting muscarinic antagonists4.2

Data are presented as % or mean±sd. BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; FEF25–75%: forced expiratory flow at 25–75% of FVC.